LGND - リガンド・ファ―マシュ―ティカルズ （Ligand Pharmaceuticals Incorporated）

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) traded at $66.80 at close of the session on Friday, 12/30/22, made a downward move of -1.17% on its previous day’s price. Looking at the stock we see that its previous close was $67.59 and the beta (5Y monthly) reads 1.07 with the day’s price range being $65.57 – $67.425. In … Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) – Analysts’ Revisions Show An Improving Sentiment Read More »

Ligand''s spinoff of OmniAb has rightsized Ligand as it faces revenue challenges. Click here to learn why I''m neutral on LGND stock at the current price.

https://www.investing.com/news/pro/ligand-pharma-pt-raised-to-90-at-roth-capital-432SI-2970362

At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) provided an overview of Ligand''s corporate structure and business following the successful spin-off of its OmniAb antibody discovery business. Management also introduced 2023 financial guidance . Related: Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger . The … Full story available on Benzinga.com

https://www.investing.com/news/pro/ligand-pharma-pt-raised-to-65-at-jpmorgan-432SI-2958221

https://www.investing.com/news/pro/ligand-pharma-pt-raised-to-65-at-jpmorgan-432SI-2958221

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this event.

Ligand Pharmaceuticals, Inc. (NASDAQ:NASDAQ:LGND) Q3 2022 Earnings Conference Call November 07, 2022, 04:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew…

WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc (LGND) announced earnings for third quarter that decreased from last year but beat the Street estimates.The company''s bottom line came in at $0.40…

Ligand Pharmaceuticals press release (LGND): Q3 Non-GAAP EPS of $0.41 misses by $0.02.Revenue of $66.09M (-4.0% Y/Y) beats by $27.76M.Ligand repurchased $38.6 million in…

Ligand Pharmaceuticals (LGND) is an intriguing but complicated business. Read why there is uncertainty about potential appeal despite a pullback in the shares.

https://www.investing.com/news/pro/ligand-pharma-pt-lowered-to-175-at-roth-capital-432SI-2885151

First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe Ligand Pharmace…

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen

EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that was discovered by Janssen scientists